Interviews

Darin J. Messina Ph.D

2024-05-21

Despite common misconceptions, the aesthetic field is deeply rooted in science, not merely vanity. We prioritize technologies that address unmet needs within the aesthetic space, ensuring our offerings stand out for their safety and effectiveness.

Amit Yadav

Chief Executive Officer

GE HealthCare, Australia & New Zealand

2024-05-21

Since our separation, GE HealthCare has become intensely focused on patients and patient outcomes, and innovative technology is an important part of that.

Kenneth Lim

General Manager & Refinery Director

Neste Singapore

2024-05-20

We have declared our goal to make all our production facilities globally carbon neutral by 2035 and have launched over 100 initiatives to achieve this.

Matthew Joyce

Senior Vice President - Lubricants & Specialties

HF Sinclair

2024-05-20

We have established a dedicated thermal management team and are set to launch a new product line aimed at improving data center energy efficiency. This initiative involves innovative cooling solutions that involve immersing servers in specially designed fluids to dissipate heat more effectively, thus reducing the massive energy consumption typically associated with cooling systems.

Vance Darr

Director of Health, Safety, Environmental and Security (HSES)

Kuraray America, Inc.

2024-05-20

The emphasis on carbon neutrality and the practical application of carbon pricing in project assessments demonstrate Kuraray's proactive stance in balancing economic viability with environmental responsibility.

Eric Johnson

CEO

JSR Corporation

2024-05-20

We saw the chance to disrupt the lengthy and costly process of bringing therapeutics from discovery to patient by offering innovative services and leveraging our R&D capabilities.

Dirk Bontridder

CEO

PerkinElmer

2024-05-20

Our OneSource services offering exemplifies how AI can optimize operations within biopharma R&D labs. By relieving scientists from the burdens of instrument complexity and maintenance, we enable them to focus on their primary objective: drug development.

Adam Elsesser

Co-Founder, President & CEO

Penumbra

2024-05-20

Our goal is to significantly expand access to CAVT so patients are able to get more advanced treatment quickly, potentially resulting in better care.

Sanjeev Rastogi

CEO

Arxada

2024-05-17

Our technologies are also pivotal in public health, illustrated by their use in combating the spread of COVID-19 through sanitization. This example highlights the indispensable role of microbial control in maintaining the quality and safety of numerous aspects of our daily environment.

Stephen Gillett

Chairman & CEO

Verily

2024-05-17

Verily Viewpoint is part of our comprehensive suite for enhancing clinical research, including partnerships with biopharmaceutical companies to optimize clinical trials through technology. This encompasses patient recruitment, consent processes, and clinical trial management.

Pagina 49 din 154